Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1461-1480 of 1,738 trials

Nasopharyngeal Cancer: Nivolumab Treatment Study

We are studying the effectiveness of Nivolumab for patients with nasopharyngeal cancer who have progressed after chemotherapy. We also want to understand how safe this treatment is for these patients.

Nasopharyngeal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Throat and Larynx Cancer: Low-Dose Radiation Therapy

We are studying a new treatment combining low doses of radiation and chemotherapy for patients with advanced throat and larynx cancer. The goal is to see if this approach improves treatment outcomes and is well-tolerated.

Throat and Larynx Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Opioid Use Disorder: Daridorexant Treatment

We are studying whether daridorexant can help reduce illicit substance use in people with opioid use disorder already on buprenorphine. The trial also looks at improvements in cravings, withdrawal symptoms, and overall treatment retention.

Opioid Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsStandard MedicinesPsychiatry

Type 1 Diabetes: Fenofibrate Study for Children

We are testing whether fenofibrate can help maintain beta cell function in children newly diagnosed with type 1 diabetes. The study also looks at the safety of this medication for young patients.

Type 1 Diabetes1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyPediatrics

Breast Cancer Diagnosis: Contrast-Enhanced Spectral Mammography

We are evaluating a new imaging method to see if it improves the accuracy of breast cancer diagnosis. This may help reduce the number of unnecessary biopsies for suspicious lesions.

Breast Lesions6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Alcohol Use Disorder: Psilocybin Treatment

We are studying if a single dose of psilocybin can help reduce heavy drinking in people with alcohol use disorder. This trial compares the effects of psilocybin to a placebo over 12 weeks.

Alcohol Use Disorder>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Grass Pollen Allergy: CLU-RX-PHL Treatment

We are testing a new subcutaneous treatment for people with grass pollen allergy. The study aims to find the most effective and safest dose to help manage allergy symptoms.

Allergic Rhinitis Due to Pollen6-12 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergologyInternal Medicine

Grass Pollen Allergy: Sublingual Immunotherapy Study

We are evaluating a new sublingual treatment for people with grass pollen allergies to see if it effectively reduces allergy symptoms. The study will also assess the safety of different doses.

Allergic Rhinitis due to PollenEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergology

Chronic Inflammatory Demyelinating Polyneuropathy: DNTH103 Treatment Study

We are studying a new treatment called DNTH103 for adults with Chronic Inflammatory Demyelinating Polyneuropathy. The trial aims to see if it can help reduce relapses and improve overall health compared to a placebo.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

5-Aminolevulinic Acid (5-ALA) for Brain Tumors in Kids

We are studying the safety of 5-ALA during surgeries for children and adolescents with brain tumors. The trial will help us understand how well it identifies tumor cells and its effects on young patients.

Brain Tumor>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

Papillary Craniopharyngioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Surgery and Immune Response: Low-Dose Interferon-alfa2a Study

We are investigating whether low-dose Interferon-alfa2a can improve immune function and recovery in patients undergoing surgery. This study looks at immune cell changes and recovery quality compared to a placebo.

Colon Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Advanced Basal Cell Carcinoma: Cemiplimab Treatment Study

We are studying the effectiveness and safety of Cemiplimab for patients with advanced basal cell carcinoma. This trial aims to see how well it works as a first-line treatment and to identify factors that may affect treatment outcomes.

Basal Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Glioblastoma: Radiodynamic Therapy with 5-Aminolevulinic Acid

We are testing a new treatment combining radiodynamic therapy and 5-Aminolevulinic acid for patients with a first recurrence of glioblastoma. The goal is to find the highest safe dose and ensure it can be tolerated.

Recurrent Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Choosing Chemotherapy

We are exploring a new approach to select between two chemotherapy options for patients with metastatic colorectal cancer. This study will help us understand how well these treatments work and their potential side effects.

MSS/pMMR Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Knee Cartilage Damage: UC-MSC Treatment

We are studying a new treatment using stem cells from umbilical cord tissue for people with cartilage damage in the knee. The trial aims to evaluate the safety and effectiveness of this approach.

Knee Cartilage Defect1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Idiopathic Hypersomnia: TAK-360 Study

We are testing a new medication, TAK-360, for people with idiopathic hypersomnia to see if it helps reduce excessive daytime sleepiness and improve overall condition. The study will also monitor the safety and tolerability of the treatment.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteNeurology

Post-COVID-19 Syndrome: Vericiguat Study

We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology